Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib with Temozolomide and Radiation in Newly Diagnosed Glioblastoma
NCT00662506Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2008
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cediranib in glioblastoma (GBM), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival at Day 218 and Safety Profile and Optimal Dose. Started Apr 2008; status: completed.
02
Drugs
cediranib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00662506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662506.